Los Angeles Allergist

Los Angeles Allergist

Alan Khadavi, MD, APC
  • Home
  • Meet Dr. Khadavi
  • Conditions We Treat
  • Your First Visit
  • Insurance Accepted
  • Allergy and Asthma Info
    • Asthma Info
    • Allergic Rhinitis
    • Allergic Triggers
  • Blog
  • Media
  • Contact Us

9001 Wilshire Blvd. Suite 204
Beverly Hills, CA 90211
Phone: 310-282-8822

15450 Ventura Blvd. Suite 102
Sherman Oaks, CA 91403
Phone: 818-528-7776

January 21, 2020 by Alan Khadavi

New treatments for eczema on the horizon

Eczema is an inflammatory skin disease that results in a rash and itching. This impacts a patients quality of life including depression, sleep disturbances and even suicidal ideation.  Treatments include, moisturizers, topical steroids and calineurin inhibitiors. Despite treatment, many patients still suffer.  Advances in recent years have brought new medications, Dupilumab and Eucrisa. Although they have given great benefit to many patients, there still are patients who do not respond to these medications.

Atopic dermatitis is a multifactorial disorder that has various subtypes, there isn’t a “one size fits all” treatment. Dupixent targets IL-4/IL-13, new treatments are on the horizon that can target other cytokines that can play a role in eczema.  Below we will discuss some new medications that are being studied.

Nemolizumab, an IL-31 antibody, targets the “itch” cytokine. Studies are ongoing to see if this can alleviated the persistent itch.

A TSLP inhibitor, tezepelumab, had some disappointing results in a phase 2 clinical trial. Nevertheless trials are still being conducted and trials for asthma have shown favorable results.

Etokimab, is an anti-IL-33 monoclonal antibody which has shown some favorable results. Trials are currently ongoing.

Fezakinumab is an IL-22 blocking monoclonal antibody. The Th22 pathway is considered a key immune driver of atopic dermatitis.  Fezakinumab has shown reversal of multiple pathological features of atopic dermatitis skin as well as a reduced overall inflammatory burden.

Ustekinumab, a human monoclona antibody inhibiting the shared p40 subunit of IL-12 and IL-23 is an effective drug for psoriasis because it blocks IL-23.  Bimekizumab, another monoclonal specific for both IL017a and IL-17f is also effective for psoriasis.

Baricitinib, a JAK 1/2 antagonist was recently approved for rheumatoid arthritis was was the first oral JAK inhibitor to progress to phase 3 clinical trials for atopic dermatitis. In phase 2 trials, Baricitinib, achieved 50% or more reduction in Eczema scores compared to placebo. Upadacitinib, a selective JAK1 inibitor showed efficacy in phase 3 trials for Rheumatoid Arthritis, clinical trials showed improvement for eczema as well.  Abrocitinib is another specific JAK1 inhibitor tested for atopic dermatitis.

Histamine 4 receptor antihistamines has an entirely different mechanism of action. They antagonize H4R, which plays a role in Th2 and Th17 inflammation and itching. ZPL-3893787 showed clinical efficacy on inflammatory skin lesions in eczema. This new class of drugs show a potential as a novel therapeutic option for this disease.

Atopic dermatitis is a heterogenous disease. Different therapeutic approaches may be necessary for different patient subsets, including a personalized approach or dual cytokine targeting. Dupixent is currently the mainstay of treatment until other drugs are approved.  Investigations of these various treatments will help dissect the complex contribution of various cytokines to atopic dermatitis and improve long term disease management and prevention of flares.

Filed Under: atopic dermatitis, Blog

alan-khadavi
Dr. Alan Khadavi
Allergy & Asthma Specialist

Latest Posts

November 17, 2026

Low Dose Naltrexone for MCAS: Benefits, Risks, and Evidence

LDN for MCAS

November 13, 2026

Cardamom Allergy: Symptoms, Diagnosis, and What to Avoid

cardamom allergy

October 28, 2026

Dr. Alan Khadavi Recognized as Top Allergist in Southern California

Dr. Alan Khadavi Recognized as Top Allergist in Southern California

October 26, 2026

Which Biologic Works Best for Nasal Polyps?

best biologic for nasal polyps

October 19, 2026

Xolair vs. Omlyclo: Cost, Effectiveness, Insurance & Switching

Xolair vs Omlyclo: Cost, Effectiveness, Insurance & Switching

October 8, 2026

Tapioca Allergy: Can Cassava Cause an Allergic Reaction?

tapioca allergy

October 8, 2026

Rhapsido for Symptomatic Dermographism: An Allergist Explains the New FDA-Approved Treatment

Rhapsido for symptomatic dermographism

October 6, 2026

Most Effective Treatments for Severe Atopic Dermatitis: New Rankings

`most-effective-treatments-severe-atopic-dermatitis

October 6, 2026

Should Airlines Be Required to Carry Epinephrine? An Allergist Explains

airline epinephrine requirement

October 2, 2026

Ketotifen for MCAS: Uses, Benefits, Side Effects, and U.S. Availability

ketotifen for MCAS

Read More Posts...

Follow Us…

© 2026 Allergy Los Angeles. All Rights Reserved · Log in · Return to top of page